A 2022 randomized trial demonstrated that 2000mg daily significantly improved global sleep quality, while other studies show it can reduce insulin resistance by up to 70% in metabolic syndrome patients
Naomi Loomis: Olympias investing in research and development on compounding other GLP-1s that may go on shortage or potential combination GLP-1s to have more accessible options, which will help keep patients on track with their weight loss and diabetes management
The FDA does not review it for safety, quality, or whether it works, and it is not the same product as Mounjaro or Zepbound
F., Busby-Whitehead, J., et al
Caroline Apovian, co-director of the Center for Weight Management and Wellness at Harvard-affiliated Brigham and Women's Hospital, is hearing similar accounts from her own patients, especially about cravings for alcohol and sweets